XML 29 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS
3 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Certain Financial Statement Items

NOTE 3. COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS

 

Inventory

 

Inventory is stated at the lower of cost (first-in, first-out) or market and consists of the following (in thousands):

 

   

September 30, 

2015 

 

June 30, 

2015 

Raw materials /purchased components   $ 1,915     $ 2,025  
Work in process     1,007       1,030  
Sub-assemblies /finished components     1,113       1,095  
Finished goods     216       160  
Total inventory   $ 4,251     $ 4,310  

 

Intangibles

 

Intangibles consist of the following (in thousands):

 

   

September 30,

2015 

 

June 30, 

2015 

Capitalized software development costs   $ 73     $ 73  
Covenant not to compete     52       52  
Trade name     54       54  
Customer list and backlog     316       316  
Patent-related costs     97       96  
Total intangibles   $ 592     $ 591  
       Less accumulated amortization     (80 )     (44 )
    $ 512     $ 547  

 

Capitalized software development costs relate to internally developed software, which are being amortized over the estimated product life of the underlying product which was released for sale during the fourth quarter of fiscal 2015. Both the covenant not to compete and the customer list and backlog relate to assets acquired in conjunction with the business acquisitions more fully described in Note 2 above and are being amortized over various periods not to exceed ten years. The trade name relates exclusively to Fineline Molds and has an indefinite life, subject to impairment loss assessment annually, or more frequently if certain conditions exist. Patent-related costs consist of legal fees incurred in connection with patent applications, and will be amortized over the life of the applicable patent upon its issuance, or expensed immediately in the event the patent office denies the issuance of the patent.